This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tannock IF et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502–1512
Beer TM et al. (2004) Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 91: 1425–1427
Joly F and Tannock IF (2004) Chemotherapy for patients with hormone refractory prostate cancer. Ann Oncol 15: 1582–1584
Petrylak DP (2004) Treatment options for advanced and high-risk prostate cancer. In Proceedings of the Changing Paradigms in Prostate Cancer Symposium: 2004 October 9; London
Acknowledgements
The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author has provided docetaxel for use in a neoadjuvant trial in localized prostate cancer with poor prognosis.
Rights and permissions
About this article
Cite this article
Sella, A. Can docetaxel plus estramustine prolong the survival of men with metastatic hormone-refractory prostate cancer?. Nat Rev Urol 2, 18–19 (2005). https://doi.org/10.1038/ncpuro0064
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpuro0064